At the J.P. Morgan Healthcare Conference 2026, Boston Scientific described the significant growth and market success of its pulsed field ablation (PFA) offerings, including the FARAWAVE and FARAPULSE PFA catheters, on 13 January.
Boston Scientific indicated double-digit growth for its PFA portfolio, with 15% growth expected to continue for at least another three years. Currently, Boston Scientific is the US market leader for PFA devices.
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
The high growth of the PFA market has been driven by the high number of atrial fibrillation patients in the US and worldwide. During the conference, Boston Scientific indicated a population of over 10 million atrial fibrillation patients in the US alone, with over 60 million worldwide. Currently, penetration for PFA and related technologies to treat heart arrythmias is very low, representing a very large unaddressed market which Boston Scientific is confident it can lead in with its PFA portfolio.
Boston Scientific expects incredibly high growth for its PFA devices, driven by increased usage of its existing catheters to address the large unaddressed patient population, and approvals of new PFA catheters for expanded indications, including the recent US Food and Drug Administration (FDA) approval of the FARAPOINT catheter to treat patients with atrial flutter. The company has also announced its intention to expand indications to other arrythmias, including ventricular tachycardia.
In addition to growing the PFA segment through new indications and further penetration of the atrial fibrillation patient population, Boston Scientific also announced its intention to expand into ambulatory surgical centers. As additional states approve their usage, Boston Scientific believes that this represents another unaddressed market where PFA can be used.
Entering 2026, Boston Scientific is poised to succeed within the PFA market. The current line of devices has seen incredible growth since its introduction to the market with no signs of slowing in the short term. As Boston Scientific expands indications and continues to expand the patient population, it is likely to continue its market leadership in PFA.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare Conference 2026. Sign up here to receive a comprehensive report after the conference.
